Thanks Temp, makes sense. One thing is for sure, with the release of very good data from the PDD at a CTAD conference (and the risk of a major lawsuit on bad news) I doubt Dr M is holding back data due to average or subpar data from both RS and PDD. In light of this your opinion is as solid as any other out there!
Interesting post, Phil, thanks for your thoughts. I appreciate analyses that take into account things that haven't happened as well as things that have.
As for Parkinson's, it would not require much to extend your reasoning to suggest the possibility of a PD/PDD/Fragile x/Other basket trial based on a common MOA and biomarker.